NEW YORK, June 3, 2026, 08:05 EDT
AN2 Therapeutics Inc (ANNX) shares ended at $4.07, slipping about 3% in the last session. Investors are waiting for CEO Eric Easom’s talk at the Jefferies Global Healthcare Conference this Thursday. The Nasdaq biotech had a market cap near $139 million before the U.S. open.
The timing is notable. AN2 said Chief Executive Eric Easom is set to present June 4 at 12:50 p.m. ET. That puts management in front of investors soon, with a chance to update on the pipeline, which covers blood disease, infectious disease and early oncology.
No major company press release has landed in the last 24 to 48 hours. Late Tuesday, a Form 4 showed Principal Accounting Officer Sarah Joanne Williams sold 265 shares at $4.43 on May 29. The sale was to cover tax withholdings tied to RSUs. She still held 66,583 shares after the move.
Investors now turn to the next steps. AN2 last month said it expects second-quarter data from two studies of its oral AN2-502998 in chronic Chagas disease: a Phase 1 first-in-human trial and a non-human primate efficacy study. Oral epetraborole is also set for a Phase 2 trial in polycythemia vera in the third quarter.
AN2 expects to move three programs into Phase 2 this year and report multiple data readouts before its cash lasts into 2029, Easom said in May. The company finished March with $85.3 million in cash, equivalents and investments, after a $40 million gross raise in a private placement.
Leerink Partners gave a boost to AN2 this week, upgrading the stock to outperform on May 14, according to Benzinga. The firm also put out a $9 price target. Price targets are guesses by analysts, not promises.
Competitive dynamics are uneven. Insmed’s Arikayce has FDA approval for refractory MAC lung disease, a type of nontuberculous mycobacterial infection. AN2 is focused on Mycobacterium abscessus, where it says there is no FDA-approved treatment.
AN2 would enter a crowded market if epetraborole moves ahead in polycythemia vera. Incyte’s Jakafi/Jakafi XR is approved for adults with PV who did not respond to or could not take hydroxyurea. PharmaEssentia’s Besremi is also cleared for adults with PV.
M. abscessus is on the radar for the company. AN2 said in January the FDA cleared an Oregon Health & Science University investigational new drug application for a 90-patient trial, run by an outside academic team while AN2 supports it. Dr. Kevin Winthrop, a public health and infectious diseases professor at OHSU, said patients need more oral therapies that are “efficacious and well tolerated.” AN2 Therapeutics, Inc
Downside risks are clear. AN2 is still in the clinic with no approved drug, and shares can move on anything from trial enrollment to timing, safety, or early efficacy shifts. The company has cautioned that results may not match early or preclinical data. It also flagged risks in investigator-led studies and said regulatory approval is not guaranteed.
The stock isn’t trading so much on current revenue now, but more on what evidence turns up. The next round for investors looks like management’s Jefferies update, then Chagas data, and later the expected Phase 2 start in polycythemia vera.
